In a week that sees the MHRA and CRUK publish critical information about the UK’s clinical research environment post-Brexit, ABPI's Deputy Chief Scientific Officer Dr Sheuli Porkess explores what it means for the pharmaceutical industry.
17 Jul 2018
Parliament has voted in favour of amendment NC17 to the Trade Bill that will make it a negotiating objective for the UK Government to seek the UK's participation in the European medicines regulatory network.
12 Jul 2018
The UK government have today published a White Paper detailing their position on ‘The Future Relationship between the United Kingdom and the European Union’.
13 Jul 2018
Pharmaceutical companies continue to plan for the UK’s exit from the EU. As they do, the terms on which the UK will leave - and the terms of the future relationship – remain uncertain.
The UK’s plans to leave the European Union (EU) and the EU’s single market could have serious implications for patients’ access to medicines and medical technologies.
This briefing explores how UK and EU citizens could be affected by the disruption in trade that could result from the UK’s exit from the EU, as well as in the event of lack of cooperation in the regulation of medicines and devices between the EU and the UK post Brexit.
The following Executive Summary two page report and the detailed report - capture the positive approach and can do attitude of all participants and reflect the desire to make a success of the opportunities ahead of us. It’s a record of a snapshot in time of our developing thinking rather than as a completed manifesto for the years ahead.
02 Jul 2018
Simon Stevens appeared on the Andrew Marr Show on Sunday 1 July and was asked about preparations for Brexit and contingency planning for a no-deal scenario to ensure the continued supply of medicines to the UK.
The ABPI is calling on the UK’s political leaders to ensure that the roadmap for the UK leaving the EU secures the future of our country’s pharmaceutical industry.
A joint policy document on the potential impact of the United Kingdom’s exit from the European Union from eleven associations representing the European and British life science industry, including the ABPI.
This OHE Consulting report, prepared for the ABPI and the BioIndustry Association, explores the consequences of the exit of the United Kingdom and from the European Union on public health in the UK and in the EU. It also provides an estimate of the economic impact for pharmaceutical companies.
21 Jun 2016
The Association of the British Pharmaceutical Industry (ABPI) and a group of leaders from ABPI member companies have joined more than 1,280 business executives, including directors from 51 FTSE 100 companies, in signing a letter backing the UK's membership of the EU.